On August 13, 2024, Brian Dorsey, Chief Operating Officer of ARS Pharmaceuticals Inc (SPRY, Financial), sold 30,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 6,024 shares of the company.
ARS Pharmaceuticals Inc (SPRY, Financial) is focused on developing novel drug products to improve the lives of patients by enabling faster and more effective treatment for severe allergic reactions. The company's primary product, epinephrine, is used in emergency treatments for anaphylactic reactions.
Over the past year, Brian Dorsey has sold a total of 30,000 shares and has not made any purchases of the company's stock. The insider transaction history for ARS Pharmaceuticals Inc shows a trend with 6 insider buys and 28 insider sells over the past year.
Shares of ARS Pharmaceuticals Inc were trading at $13 on the day of the sale, giving the company a market cap of approximately $1.31 billion.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's stock performance and valuation.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
